Dimensional Fund Advisors
OMED

Dimensional Fund Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Dimensional Fund Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-85,741
Closed -$64K – 3513
2018
Q4 		$64K Sell
85,741
-8,500
-9% -$12.8K ﹤0.01% 3384
2018
Q3 		$200K Buy
+94,241
New +$226K ﹤0.01% 3311

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors's OMED Position: Q1 2019 in Review

Dimensional Fund Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 85,741 shares — an estimated $64K sold.

Dimensional Fund Advisors first reported a position in OMED in Q3 2018 and held it in 2 quarters. The position peaked at $200K in Q3 2018. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

  • Dimensional Fund Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Dimensional Fund Advisors sold 85,741 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $64K.
  • Dimensional Fund Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Dimensional Fund Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $200K in Q3 2018.
  • 41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Dimensional Fund Advisors's 13F filing for Q1 2019, filed 10 May 2019.